Business Context and Reporting Period
This Form 8-K Current Report was filed by Acadia Healthcare Company, Inc. on June 29, 2022, regarding events occurring on June 28, 2022. The filing primarily addresses corporate governance changes involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on director appointments rather than financial performance.
Material Changes
- Board Composition: The Board of Directors increased the number of Class II directors from three to four.
- Director Election: R. David Kelly was elected to fill the newly created vacancy in the Class II director seat.
- Term Details: Mr. Kelly's term will expire at the Company's annual meeting of stockholders in 2025.
- Committee Assignments: The Board has not named Mr. Kelly to any committees at this time.
Outlook, Risks, and Management Commentary
Management Commentary: The filing details Mr. Kelly's professional background, noting his roles as founder and managing partner of StraightLine Realty Partners, founder/chairman/CEO of Croesus and Company, and managing director/co-founder of Serra Real Estate Capital, LLC. He previously served as a founding partner of Carleton Residential Properties from 1996 to 2011.
Compensation: Mr. Kelly will receive compensation in accordance with the Company's existing plan for non-employee directors, as detailed in the definitive proxy statement filed on April 8, 2022.
Risks and Contingencies: No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of R. David Kelly's election (June 28, 2022).
- Confirm the expiration date of the Class II director term (2025 annual meeting).
- Review the definitive proxy statement filed on April 8, 2022, for details on the non-employee director compensation plan.
- Note that no committee assignments were made to the new director at the time of filing.